AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Emory University, Winship Cancer Institute, National Taiwan University, National Taiwan University Hospital, St George Hospital, Kansai Medical University, Seoul National University Hospital, Olivia Newton-John Cancer Research Institute, Shikoku Cancer Center, National Cancer Center Hospital East, AstraZeneca (United Kingdom), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2220335203